Experiment 67643
Worktypes
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Empty organism |
| Citation | REGINSTER,JY: DEROISY,R: ROVATI,LC: LEE,RL: LEJEUNE,E: BRUYERE,O: GIACOVELLI,G: HENROTIN,Y: DACRE,JE: GOSSETT,C:. (2001). LONG-TERM EFFECTS OF GLUCOSAMINE SULPHATE ON OSTEOARTHRITIS PROGRESSION: A RANDOMISED, PLACEBO-CONTROLLED CLINICAL TRIAL.. 357(9252) |
| Amount utilized | |
| Compound isolated | |
| Disease | A RANDOMISED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL, IN WHICH 212 PATIENTS WITH KNEE OSTEOARTHRITIS WERE RANDOMLY ASSIGNED 1500 MG SULPHATE ORAL GLUCOSAMINE OR PLACEBO ONCE DAILY FOR 3 YEARS. WEIGHTBEARING, ANTEROPOSTERIOR RADIOGRAPHS OF EACH KNEE IN FULL EXTENSION WERE TAKEN AT ENROLMENT AND AFTER 1 AND 3 YEARS. MEAN JOINT-SPACE WIDTH OF THE MEDIAL COMPARTMENT OF THE TIBIOFEMORAL JOINT WAS ASSESSED BY DIGITAL IMAGE ANALYSIS, WHEREAS MINIMUM JOINT-SPACE WIDTH-IE, AT THE NARROWEST POINT-WAS MEASURED BY VISUAL INSPECTION WITH A MAGNIFYING LENS. SYMPTOMS WERE SCORED BY THE WESTERN ONTARIO AND MCMASTER UNIVERSITIES (WOMAC) OSTEOARTHRITIS INDEX. THE 106 PATIENTS ON PLACEBO HAD A PROGRESSIVE JOINT-SPACE NARROWING, WITH A MEAN JOINT-SPACE LOSS AFTER 3 YEARS OF -0.31MM. THERE WAS NO SIGNIFICANT JOINT-SPACE LOSS IN THE 106 PATIENTS ON GLUCOSAMINE SULPHATE: -0.06MM. SIMILAR RESULTS WERE REPORTED WITH MINIMUM JOINT-SPACE NARROWING. AS ASSESSED BY WOMAC SCORES, SYMPTOMS WORSENED SLIGHTLY IN PATIENTS ON PLACEBO COMPARED WITH THE IMPROVEMENT OBSERVED AFTER TREATMENT WITH GLUCOSAMINE SULPHATE. |
| Dose amount | 1.5 GM |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Gender | GIVEN TO BOTH SEXES |